US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
14.9.2022 18:51:00 EEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical study of YH001 in combination with envafolimab and doxorubicin for the treatment of sarcoma patients, including patients who have not received prior therapy.
The Phase 1/2 trial will assess the safety and efficacy of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma and assess the safety and efficacy of the combination of YH001, envafolimab and doxorubicin in the common sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma.
“YH001 was discovered using Biocytogen’s evidence-based in vivo drug efficacy screening platform and has demonstrated a favorable safety profile and promising anti-tumor activity in combination with a PD-1 antibody in an earlier phase 1 clinical study,” said Rong Chen, M.D., Ph.D., VP of Biocytogen, CEO and CMO of Eucure Biopharma. “As an antibody targeting the validated checkpoint CTLA-4, YH001 is expected to play a very important role in immune-oncology therapy. We are glad to learn that the combination therapy of YH001 + envafolimab and doxorubicin received IND approval by the FDA.”
“We are pleased to receive approval from the FDA to initiate our triplet combination therapy study in sarcoma, which includes our potentially best-in-class CTLA-4 antibody YH001 and the only subcutaneous checkpoint inhibitor approved anywhere in the world, envafolimab,” said Charles Theuer, M.D., Ph.D., TRACON’s Chief Executive Officer. “We look forward to enrolling patients in this study and giving patients additional options for their sarcoma treatment.”
About YH001
YH001 is an IgG1 antibody targeting CTLA-4 that was invented by Biocytogen, the parent company of Eucure Biopharma, and licensed by TRACON. YH001 has shown enhanced antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) in vitro when compared with ipilimumab. In preclinical studies YH001 demonstrated superior T cell activation and superior tumor growth inhibition activity compared to ipilimumab as a single agent and when combined with a PD-(L)1 antibody in human transgenic mouse tumor models. In these models, single agent YH001 depleted regulatory T cells and increased CD8+ T cells in tumor tissue. YH001 has been dosed as a single agent in a Phase 1 trial in China (NCT04699929) and in combination with the PD-1 antibody toripalimab in a Phase 1 trial in Australia (NCT04357756).
About Eucure Biopharma
As a wholly owned subsidiary of Biocytogen, Eucure Biopharma undertakes the mission of clinical development for Biocytogen’s R&D pipelines. Relying on a strong clinical development team and extensive clinical development experience, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications. The company has established a product pipeline for more than 10 targets, with two products in launched phase II multi-regional clinical trials (MRCT) and two in phase I. For details, please visit www.eucure.com.
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai and Boston, USA. For more information, please visit www.biocytogen.com.cn.
About TRACON
TRACON is a clinical-stage biopharmaceutical company utilizing a cost-efficient, CRO-independent, product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue-share partnership, or through franchising TRACON’s product development platform. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States or who wish to become CRO-independent. To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005548/en/
Contact information
Biocytogen
Drug Assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thermochemical Energy Storage Leader Redoxblox Rebrands as Tempo31.3.2026 10:00:00 EEST | Press release
Redoxblox, a leader in thermochemical energy storage (TCES) on a mission to electrify the world with technology that shifts the power dynamic, today announced its rebrand to Tempo. The new identity marks the company’s transition from technology development to the commercial scaling of its breakthrough electrified heat platform. The rebrand, developed in partnership with renowned creative agency Red Antler, aligns Tempo’s strategic identity with its unique ability to meet the rigorous demands of heavy industry. The name Tempo is a nod to three core pillars of the company’s value proposition: Temperature leadership, the time-shifting of energy, and the pace of both continuous industrial heat delivery and rapid innovation. “As we move from technical validation toward large-scale commercial rollout, our brand must reflect the scale of the challenge we are solving,” said Pasquale Romano, CEO of Tempo. “Tempo represents our ability to deliver the extreme temperatures industry requires while
STV Group and Post-Quantum Successfully Trial World’s First Quantum-Resilient Drones31.3.2026 10:00:00 EEST | Press release
STV Group a.s., a European defence technology integrator with platforms deployed in Ukraine and allied theatres, and Post-Quantum, the UK cybersecurity company, today announced successful testing of the world’s first quantum-safe drones for active deployment across allied theatres. As allied nations adapt to warfighting defined by autonomous systems and drones, the ability to futureproof secure communications between drones and their operators is of paramount importance. Drone swarms procured today may be stored and deployed in future operations years later. This dynamic requires drones manufactured today incorporate encryption that’s resistant to attack by both classical and quantum computers. The collaboration combines STV’s combat-tested unmanned systems and command-and-control infrastructure with Post-Quantum’s patented post-quantum cryptography and secure radio technologies. The two companies have now successfully trialled the new approach at STV’s weapons testing facility in the
Schneider Electric Joins Thread Group Board of Directors31.3.2026 10:00:00 EEST | Press release
The Thread Group, an industry alliance addressing IoT convergence, security, power, and architecture challenges, today announced that Schneider Electric has joined its Board of Directors. A member of the Thread Group since 2015, Schneider Electric will take a more active role in shaping the future of the Thread wireless networking protocol moving forward. This addition comes at a pivotal time for the organization, with Thread recently surpassing 1000 consumer products, and as we continue to see expansion into commercial markets. Thread 1.4 delivers significant benefits for commercial and industrial applications, including seamless communication, enhanced reliability, and performance in expansive IoT deployments. "The entire Thread Group will benefit from Schneider Electric’s deeper engagement in our efforts," said Vividh Siddha, President of Thread Group. "A dedicated member for more than a decade, their expertise in energy management and building automation is invaluable, especially a
Allshares Acquires Technology Company Amalia to Accelerate Innovation in Ownership and Incentive Management31.3.2026 10:00:00 EEST | Press release
Allshares, a global equity and ownership management platform, today announced the acquisition of Amalia, a France-based company specializing in sales commission and performance management software. The acquisition strengthens Allshares' platform, adding a sophisticated, rules-based engine that expands and enhances its end-to-end ownership offering. Founded in 2020, Amalia was built technology-first. Its software is centered on a powerful rules engine that enables intuitive compensation plan design, giving organizations the flexibility to model incentive structures in a fully self-service environment, unlocking new possibilities for incentive management at scale. Supporting more than 40 organizations, including Nespresso, TheFork, and Rakuten, Amalia provides real-time visibility into performance and incentive data, enabling companies to operate complex compensation programs with greater control and efficiency. “From day one, our focus has been to bring clarity to performance-based comp
Regnology Announces Next-Generation Ascend Platform with Agentic AI, Advancing the Future of Regulatory Reporting31.3.2026 09:00:00 EEST | Press release
Regnology, a global leading provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the evolution of Ascend, the next‑generation Regnology platform. This landmark release introduces a powerful agentic AI layer to the Regnology platform and formally integrates the Regnology Supervisory Hub (RSH) into the Ascend ecosystem. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330254615/en/ Launched in late 2025, Ascend is the catalyst of Regnology’s Straight-Through-Reporting (STR) vision. The initial rollout empowered financial institutions with RRH Ascend delivering intelligent data governance for proactive quality assurance, predictive insights to anticipate regulatory demands, powerful automation to execute complex workflows, and contextual collaboration for seamless human oversight. “Our position at the nexus of risk, regulation, and finance gives Regnology a unique vantage point
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom